Oppenheimer analyst Leland Gershell raised the price target on Recro Pharma (NASDAQ: REPH) to $15.00 (from $9.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE